Gilead Sciences

Gilead Sciences has pursued and achieved breakthroughs once thought impossible in medicine for more than 3 decades, with the goal of creating a healthier world for all people. At Gilead, we have pioneered more than 25 medicines since our founding in 1987 and have an expanding portfolio of investigational compounds. We have helped transform care for people living with HIV, developing the world’s first HIV single tablet regimen to treat the disease and the 1st medicines to prevent infection with the HIV virus. Our scientists are continuing to pursue new kinds of treatments, such as long-acting antivirals, and the ultimate goal: a cure. Building on our success in HIV, we applied the same tenacity to Hepatitis C virus delivering four curative treatments in less than 4 years. Today more than 4 Million people have been prescribed our HCV therapies. Through our Kite operation company in Southern California, we are on a path to a potential cure for cancer with our cutting-edge cell therapy program. Through research and development we’re creating possibilities that include a wide range of clinical studies evaluating compounds with the potential to become the next generation of life-changing medicines. We believe the impossible is not impossible. It simply hasn’t been achieved yet.

Learn More About:        Biktarvy          Epclusa          Descovy

Contact Gilead Sciences:
Jason Smith
jason.smith@gilead.com